RxDoctor Payments Data

Victoria Dunaevsky, MD

Family Medicine · Pittsburgh, PANPI 1922273929

Payments from drug & device makers

$3,251in general payments, 2019–2025

Across 175 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$541
  • Novo Nordisk$535
  • GSK$523
  • Pfizer$268
  • Lilly USA, LLC$264
  • Amgen$215
  • plus $906 from 22 others

What the payments were for

  • Food & beverage$3,22499%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,251 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$36,223
Medicare patients
106
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$83,592
EliquisApixaban70$69,176
ProliaDenosumab30$49,016
JardianceEmpagliflozin33$44,411
MyrbetriqMirabegron42$33,183
OxycontinOxycodone Hcl21$31,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$27,828
Breo ElliptaFluticasone/Vilanterol42$20,246
JanuviaSitagliptin Phosphate17$19,090
XareltoRivaroxaban16$17,216
RybelsusSemaglutide14$17,156
CreonLipase/Protease/Amylase14$16,356
MounjaroTirzepatide15$14,719
Repatha SureclickEvolocumab20$10,584
RestasisCyclosporine11$6,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$535$100,74795 claims
PfizerEliquis$268$69,17670 claims
AmgenProlia$215$49,01630 claims
GSKTrelegy Ellipta, Breo Ellipta$523$48,07486 claims
Boehringer IngelheimJardiance$15$44,41133 claims
Astellas Pharma US IncMyrbetriq, Veozah$100$39,78454 claims
AbbVieCreon, Restasis, Synthroid$541$24,69866 claims
MerckJanuvia$86$19,09017 claims
Lilly USA, LLCMounjaro$264$14,71915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →